vs
英特格（ENTG）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
英特格的季度营收约是Royalty Pharma plc的1.3倍（$823.9M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 6.0%，领先28.4%），Royalty Pharma plc同比增速更快（4.8% vs -3.1%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 3.4%）
英特格是面向半导体及其他高科技行业的材料供应商，全球员工约8000人，总部位于美国马萨诸塞州比勒里卡。公司在全球多国及地区布局生产、客户服务与研发设施，覆盖美国、加拿大、中国、德国、以色列、日本、马来西亚、新加坡、韩国、中国台湾等地。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
ENTG vs RPRX — 直观对比
营收规模更大
ENTG
是对方的1.3倍
$622.0M
营收增速更快
RPRX
高出7.8%
-3.1%
净利率更高
RPRX
高出28.4%
6.0%
两年增速更快
RPRX
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $823.9M | $622.0M |
| 净利润 | $49.4M | $214.2M |
| 毛利率 | 43.8% | — |
| 营业利润率 | 12.7% | 62.4% |
| 净利率 | 6.0% | 34.4% |
| 营收同比 | -3.1% | 4.8% |
| 净利润同比 | -51.7% | 2.9% |
| 每股收益（稀释后） | $0.33 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ENTGRPRX
| Q4 25 | $823.9M | $622.0M | ||
| Q3 25 | $807.1M | $609.3M | ||
| Q2 25 | $792.4M | $578.7M | ||
| Q1 25 | $773.2M | $568.2M | ||
| Q4 24 | $849.8M | $593.6M | ||
| Q3 24 | $807.7M | $564.7M | ||
| Q2 24 | $812.7M | $537.3M | ||
| Q1 24 | $771.0M | $568.0M |
净利润ENTGRPRX
| Q4 25 | $49.4M | $214.2M | ||
| Q3 25 | $70.5M | $288.2M | ||
| Q2 25 | $52.8M | $30.2M | ||
| Q1 25 | $62.9M | $238.3M | ||
| Q4 24 | $102.2M | $208.2M | ||
| Q3 24 | $77.6M | $544.0M | ||
| Q2 24 | $67.7M | $102.0M | ||
| Q1 24 | $45.3M | $4.8M |
毛利率ENTGRPRX
| Q4 25 | 43.8% | — | ||
| Q3 25 | 43.5% | — | ||
| Q2 25 | 44.4% | — | ||
| Q1 25 | 46.1% | — | ||
| Q4 24 | 45.6% | — | ||
| Q3 24 | 46.0% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 45.6% | — |
营业利润率ENTGRPRX
| Q4 25 | 12.7% | 62.4% | ||
| Q3 25 | 15.2% | 70.1% | ||
| Q2 25 | 13.4% | 36.3% | ||
| Q1 25 | 15.8% | 94.0% | ||
| Q4 24 | 17.6% | 60.9% | ||
| Q3 24 | 16.9% | — | ||
| Q2 24 | 16.0% | 50.2% | ||
| Q1 24 | 15.3% | -13.0% |
净利率ENTGRPRX
| Q4 25 | 6.0% | 34.4% | ||
| Q3 25 | 8.7% | 47.3% | ||
| Q2 25 | 6.7% | 5.2% | ||
| Q1 25 | 8.1% | 41.9% | ||
| Q4 24 | 12.0% | 35.1% | ||
| Q3 24 | 9.6% | 96.3% | ||
| Q2 24 | 8.3% | 19.0% | ||
| Q1 24 | 5.9% | 0.8% |
每股收益（稀释后）ENTGRPRX
| Q4 25 | $0.33 | $0.49 | ||
| Q3 25 | $0.46 | $0.67 | ||
| Q2 25 | $0.35 | $0.07 | ||
| Q1 25 | $0.41 | $0.55 | ||
| Q4 24 | $0.67 | $0.46 | ||
| Q3 24 | $0.51 | $1.21 | ||
| Q2 24 | $0.45 | $0.23 | ||
| Q1 24 | $0.30 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $360.4M | $618.7M |
| 总债务越低越好 | $3.7B | $9.0B |
| 股东权益账面价值 | $4.0B | $9.7B |
| 总资产 | $8.4B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.94× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资ENTGRPRX
| Q4 25 | $360.4M | $618.7M | ||
| Q3 25 | $399.8M | $938.9M | ||
| Q2 25 | $376.8M | $631.9M | ||
| Q1 25 | $340.9M | $1.1B | ||
| Q4 24 | $329.2M | $929.0M | ||
| Q3 24 | $432.1M | $950.1M | ||
| Q2 24 | $320.0M | $1.8B | ||
| Q1 24 | $340.7M | $843.0M |
总债务ENTGRPRX
| Q4 25 | $3.7B | $9.0B | ||
| Q3 25 | $3.8B | $8.9B | ||
| Q2 25 | $4.0B | $8.0B | ||
| Q1 25 | $4.0B | $7.6B | ||
| Q4 24 | $4.0B | $7.6B | ||
| Q3 24 | $4.1B | $7.6B | ||
| Q2 24 | $4.1B | $7.6B | ||
| Q1 24 | $4.2B | $6.1B |
股东权益ENTGRPRX
| Q4 25 | $4.0B | $9.7B | ||
| Q3 25 | $3.9B | $9.6B | ||
| Q2 25 | $3.8B | $9.5B | ||
| Q1 25 | $3.7B | $9.8B | ||
| Q4 24 | $3.7B | $10.3B | ||
| Q3 24 | $3.6B | $10.3B | ||
| Q2 24 | $3.5B | $9.8B | ||
| Q1 24 | $3.4B | $9.9B |
总资产ENTGRPRX
| Q4 25 | $8.4B | $19.6B | ||
| Q3 25 | $8.4B | $19.3B | ||
| Q2 25 | $8.4B | $18.3B | ||
| Q1 25 | $8.4B | $17.6B | ||
| Q4 24 | $8.4B | $18.2B | ||
| Q3 24 | $8.5B | $18.0B | ||
| Q2 24 | $8.3B | $17.7B | ||
| Q1 24 | $8.4B | $16.1B |
负债/权益比ENTGRPRX
| Q4 25 | 0.94× | 0.92× | ||
| Q3 25 | 0.99× | 0.93× | ||
| Q2 25 | 1.05× | 0.84× | ||
| Q1 25 | 1.06× | 0.78× | ||
| Q4 24 | 1.08× | 0.74× | ||
| Q3 24 | 1.15× | 0.74× | ||
| Q2 24 | 1.18× | 0.78× | ||
| Q1 24 | 1.22× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.0M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $134.0M | — |
| 自由现金流率自由现金流/营收 | 16.3% | — |
| 资本支出强度资本支出/营收 | 7.0% | — |
| 现金转化率经营现金流/净利润 | 3.89× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $396.2M | — |
8季度趋势，按日历期对齐
经营现金流ENTGRPRX
| Q4 25 | $192.0M | $827.1M | ||
| Q3 25 | $249.5M | $702.6M | ||
| Q2 25 | $113.5M | $364.0M | ||
| Q1 25 | $140.4M | $596.1M | ||
| Q4 24 | $176.1M | $742.5M | ||
| Q3 24 | $197.2M | $703.6M | ||
| Q2 24 | $111.2M | $658.2M | ||
| Q1 24 | $147.2M | $664.6M |
自由现金流ENTGRPRX
| Q4 25 | $134.0M | — | ||
| Q3 25 | $182.8M | — | ||
| Q2 25 | $47.0M | — | ||
| Q1 25 | $32.4M | — | ||
| Q4 24 | $68.6M | — | ||
| Q3 24 | $115.0M | — | ||
| Q2 24 | $51.9M | — | ||
| Q1 24 | $80.6M | — |
自由现金流率ENTGRPRX
| Q4 25 | 16.3% | — | ||
| Q3 25 | 22.6% | — | ||
| Q2 25 | 5.9% | — | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 8.1% | — | ||
| Q3 24 | 14.2% | — | ||
| Q2 24 | 6.4% | — | ||
| Q1 24 | 10.4% | — |
资本支出强度ENTGRPRX
| Q4 25 | 7.0% | — | ||
| Q3 25 | 8.3% | — | ||
| Q2 25 | 8.4% | — | ||
| Q1 25 | 14.0% | — | ||
| Q4 24 | 12.7% | — | ||
| Q3 24 | 10.2% | — | ||
| Q2 24 | 7.3% | — | ||
| Q1 24 | 8.6% | — |
现金转化率ENTGRPRX
| Q4 25 | 3.89× | 3.86× | ||
| Q3 25 | 3.54× | 2.44× | ||
| Q2 25 | 2.15× | 12.06× | ||
| Q1 25 | 2.23× | 2.50× | ||
| Q4 24 | 1.72× | 3.57× | ||
| Q3 24 | 2.54× | 1.29× | ||
| Q2 24 | 1.64× | 6.45× | ||
| Q1 24 | 3.25× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ENTG
| Fabs | $516.3M | 63% |
| Equipment And Engineering | $121.8M | 15% |
| Chemical And Materials | $83.8M | 10% |
| Other | $61.7M | 7% |
| Non Semi | $40.3M | 5% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
